Why the study?
To test whether doxorubicin and cyclophosphamide adjuvant chemotherapy acutely impairs neurovascular and hemodynamic responses in women with breast cancer.
Does adjuvant chemotherapy with doxorubicin and cyclophosphamide acutely impair neurovascular and hemodynamic responses in women with breast cancer?
Does adjuvant chemotherapy with doxorubicin and cyclophosphamide acutely impair neurovascular and hemodynamic responses in women with breast cancer?
A single cycle of doxorubicin and cyclophosphamide acutely induces adverse neurovascular and hemodynamic changes, highlighting potential early mechanisms of chemotherapy-induced cardiovascular toxicity.
No takes yet. Share an insight, caveat, or question.
Acute CHT augments sympathetic activity and pressor responses; leaves open long-term CV risk implications in breast cancer.
Sales et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: